Compugen announced Monday that data presented at the American Association for Cancer Research (AACR) virtual annual meeting showed that in a Phase I study, the experimental anti-PVRIG antibody COM701 demonstrated "encouraging signals" of antitumour activity with high disease control rates. CEO Anat Cohen-Dayag remarked "we are thrilled to see durable responses in patients with extremely challenging cancer types with poor prognosis"
The ongoing trial is designed to assess the safety and tolerability of administering escalating doses of COM701 monotherapy, as well as in combination with Bristol-Myers Squibb's Opdivo (nivolumab) in patients with advanced solid tumours who have exhausted all available standard therapies. Secondary endpoints of the study include preliminary antitumour activity, pharmacokinetics and pharmacodynamics in patients with selected tumour types, including non-small-cell lung cancer, ovarian cancer, breast cancer, endometrial cancer and colorectal cancer.
According to Compugen, COM701 was well tolerated with no dose-limiting toxicities observed as a monotherapy and in combination with Opdivo. The company noted that no increased toxicity was observed in the combination arm, while no patients discontinued treatment due to toxicity. Meanwhile, a disease control rate of 69% was seen in the 16 patients given COM701 alone, which rose to 75% in the 12 subjects administered the drug in combination with Opdivo, including two confirmed partial responses. Compugen said that across the two cohorts, stable disease for over six months was seen in 21% of patients.
Ryan Sullivan, presenting author, commented "achieving durable disease control, including partial responses, is remarkable in this population and I am particularly enthusiastic about the proportion of patients in the combination arm, currently 50%, who remain on treatment." Sullivan added "these results support further investigation of targeting PVRIG with COM701 and suggest that targeting the PVRIG/TIGIT pathways may broaden the patient population that can benefit from immunotherapies."
Cohen-Dayag said "notably, the ongoing responses in microsatellite stable colorectal cancer and primary peritoneal cancer…are supportive of our biomarker-informed selection of indications for the monotherapy expansion cohorts." Compugen indicated that the monotherapy expansion cohorts are based on a biomarker-informed selection of indications, and will include non-small cell lung cancer, ovarian, breast, endometrial and colorectal cancer.
To read more Top Story articles, click here.